In vitro Immunoassays
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence
InnoSer’s In Vitro Immunoassays CRO Services:
In vitro immunoassays function as a critical tool to study various aspects of the complex immune system in the context of health and disease. Human and rodent immune cell lines and primary cells allow to evaluate the effect of investigational compounds on immune cell composition, activation status and polarisation, give a clear view on mechanisms of action, allow the identification of key biomarkers and allow early identification of potential immune toxicity.
InnoSer offers preclinical research services using a wide range of commercially available cell lines and primary rodent (splenocytes, PBMCs) and human immune cell (T cells, B cells, macrophages, monocytes, PBMCs etc.,). Immunoassays using rodent or human cell lines are efficient, relatively inexpensive, have fast turn-around times, while primary cells allow to generate translational data taking into account disease mechanisms and patient variability. InnoSer’s immunoassay capabilities include macrophage polarization, T-cell activation and proliferation assays, cytokine release assays, tumor-killing assays, and mixed lymphocyte reaction assays. These examples listed can be used prior to or in conjunction with running in vivo studies in InnoSer’s mouse models of inflammatory and/or autoimmune diseases or our portfolio of immune-oncology rodent models.
✓ Wide range of 2D or 3D in vitro immunology assays in (co-)cultures or organ-on-chip platforms in both rodent human primary (PBMC-derived) or immortalized rodent and human cell lines.
✓ Wide range of assays (macrophage polarisation, T cell, B cell activation assays, immuno-oncology, cell therapy tumor killing assays etc.,).
✓ Complementary immuno-oncology, inflammatory or autoimmune disease in vivo mouse models, and in vivo PK/PD profiling services.
Developing new, safe and efficacious therapies is an extremely intricate process. As a preclinical immunology contract research organisation (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical immunology studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.
In vitro Immunoassays Sample Data

Macrophage polarization can be studied in vitro to evaluate the mechanism of action (MoA) of novel immunotherapies.
Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on polarisation of M1 macrophages: HLA-DR expression shown as percentage (%) and (B) mean fluorescence intensity (MFI). Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on viability of macrophages showing Trametinib-induced immunotoxicity of M1 cells (C).

Macrophage polarization can be studied in vitro to evaluate the mechanism of action (MoA) of novel immunotherapies.
Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on polarization of M1 macrophages: HLA-DR expression shown as mean fluorescence intensity (MFI).

Macrophage polarization can be studied in vitro to evaluate the mechanism of action (MoA) of novel immunotherapies.
Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on viability of macrophages showing Trametinib-induced immunotoxicity of M1 cells.
Available In vitro Immunology Assays
Les personnes qui travaillent sur vos recherches
Céline Erens, docteure en immunologie, étude Directrice
Une équipe d'experts dirigée par notre ; Céline Erens, travaille à vos côtés pour vous aider à mettre en place des . La gestion des essais précliniques de vos composés phares, fondée sur une connaissance approfondie du domaine, est la solution qui vous permettra d’accélérer le développement de vos médicaments.
Yanick Fanton, docteur, directeur scientifique
En tant que directeur scientifique chez InnoSer, Yanick est responsable de toutes les études menées pour le compte des clients de l'entreprise et assure la coordination scientifique et technique.
Découvrez d'autres modèles murins liés à l'immunologie
Restez curieux : d'autres articles à découvrir
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Les sites d'InnoSer aux Pays-Bas et en Belgique sont accrédités par l'AAALAC depuis 2016 et 2020, respectivement. Pour en savoir plus sur le programme d'accréditation de l'AAALAC, cliquez ici.
![]()
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi InnoSer s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides











